- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01005849
Probiotics and the Prevention of Traveler's Diarrhea (TD)
A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea
The present study is designed to evaluate the effect of a mixture of probiotics on the prevention of traveler's diarrhea (TD) in subjects who travel to a country with a high risk for developing TD. Subjects will be asked to take one capsule containing a mixture of probiotics or a placebo capsule a day, within the week before departure, during the travel and up to 3 days after return. They will note the following outcomes in a diary: occurence of diarrhea, number and consistency of stools, duration of the diarrhea, presence of diarrhea-related symptoms and need for rescue medication.
The present study will examine if the use of the probiotics capsule reduces the occurence of traveler's diarrhea as compared to the placebo capsule.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Milan, Italy
- University of Milan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects aged 18 or over. Upper age limit set by subject's ability to participate in the study;
- Subject must give written informed consent;
- Plan to travel to a geographic area with high risk of TD with a travel duration between 12 and 14 days;
- Subjects must be willing to refrain from using anti-diarrheal medications or antibiotics during the study period, unless they become clinically indicated in which case a rescue regimen can be administered;
- Subjects willing to refrain from eating yoghurt and taking other probiotics during the study;
- Female subjects of child-bearing potential must agree to use adequate birth control during the study period. This will be defined as hormonal contraception or a double barrier-method.
Exclusion Criteria:
- Subjects who have been previously treated with PROTECFLOR® or who have participated in previous Lallemand-sponsored studies;
- Subjects who have been born in a developing country.
- Subjects with a history of substance or alcohol abuse or any other psychological condition that may, in the investigator's opinion, adversely affect their co-operation with the study;
- Subjects who receive a cholera vaccine
- Subjects with chronic diarrhea;
- Subjects with chronic disease such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) or ulcerative colitis (UC) ;
- Subjects with gastrointestinal (GI) surgery during the last 3 months;
- Subjects who took systemic antibiotic 15 days or less prior to the study;
- Subjects with immunodeficiency's or immune suppression;
- Subjects being treated for cancer with radiotherapy and/or chemotherapy;
- Subjects with organ transplants;
- Subjects treated with immunosuppressant drugs;
- Subjects receiving another probiotic preparations or having received probiotic preparations within the last 15 days;
- Subjects with tube feeding, ileostomy and colostomy;
- Subjects diagnosed Clostridium difficile colitis within the last 3 months;
- Women who are pregnant, or who will not consent to using adequate birth control during the study period;
- Women who are breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
1 Capsule to be taken once a day during the entire study period
|
Experimental: Protecflor
|
1 Capsule to be taken once a day during the entire study period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurence of traveler's diarrhea
Time Frame: 3 weeks
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and consistency of stools (normal, soft or unformed)
Time Frame: 3 weeks
|
3 weeks
|
Duration of traveler's diarrhea if occurred (# days)
Time Frame: 3 weeks
|
3 weeks
|
Presence of symptoms associated with TD (cramps, nausea, fever, blood in the stools, vomiting, bloating, flatulence, visceral pain)
Time Frame: 3 weeks
|
3 weeks
|
Need for rescue medication
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mirella Pontello, Prof., University of Milan, Milan, Italy
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- #09-prot-2-lal-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Travelers' Diarrhea
-
Intercell USA, Inc.Completed
-
Lumen Bioscience, Inc.Not yet recruiting
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.Completed
-
Centers for Disease Control and PreventionProcter and Gamble; The New York Center for Travel and Tropical MedicineTerminatedAntibiotic Resistant Infection | Diarrhea TravelersUnited States
-
Henry M. Jackson Foundation for the Advancement...Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...RecruitingDiarrhoea;Acute | Diarrhea TravelersDjibouti, Honduras, Kenya
-
RedHill Biopharma LimitedNot yet recruiting
-
Clasado Biosciences LtdWithdrawnTraveler's Diarrhea